Ascendis Pharma ASMEX:ASNDN 37 EV-to-FCF is 190.74 as of Jun. 25, 2026, which is 11% below its 10-year median of 214.09. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 330 Biotechnology companies, Ascendis Pharma AS ranks worse than 94.55% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ascendis Pharma AS's Enterprise Value is MXN242,902 Mil.
Ascendis Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1,273 Mil. Therefore, Ascendis Pharma AS's EV-to-FCF for today is 190.74.
The historical rank and industry rank for Ascendis Pharma AS's EV-to-FCF or its related term are showing as below:
MEX:ASNDN'
s EV-to-FCF Range Over the Past 10 Years
Min: 196.3 Med: 214.09 Max: 229.52
Current: 224.5
During the past 13 years, the highest EV-to-FCF of Ascendis Pharma AS was 229.52. The lowest was 196.30. And the median was 214.09.
MEX:ASNDN's EV-to-FCF is ranked worse than 94.55% of 330
companies
in the Biotechnology industry
Industry Median: 14.97
vs MEX:ASNDN: 224.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascendis Pharma AS (MEX:ASNDN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ascendis Pharma AS's PE Ratio (TTM) for today is calculated as:
Ascendis Pharma AS's share price for today is MXN3851.44.
Ascendis Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-51.316.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ascendis Pharma AS EV-to-FCF Related Terms
Ascendis Pharma AS EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ASNDN vs SMMT, BBIO, JAZZ: EV-to-FCF Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's EV-to-FCF falls into.
Ascendis Pharma AS's current Enterprise Value is MXN242,902 Mil.
Ascendis Pharma AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,273 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (MEX:ASNDN) has a EV-to-FCF of 190.74 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ascendis Pharma AS and its competitors. This is 11% below median its historical median of 214.09. Over the past decade, Ascendis Pharma AS's EV-to-FCF has ranged from 196.30 to 229.52. According to the industry distribution chart, Ascendis Pharma AS ranks #312 out of 330 companies in the Biotechnology industry, placing it in the top 94.5%.
Is Ascendis Pharma AS's EV-to-FCF too high?
Ascendis Pharma AS's current EV-to-FCF of 190.74 is 11% below median its 10-year median of 214.09. Over the past 10 years, this metric has ranged from a low of 196.30 to a high of 229.52. The Biotechnology industry median EV-to-FCF is 14.97. Ascendis Pharma AS's value of 190.74 is 1174.1% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #312 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's EV-to-FCF compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #312 out of 330 companies for EV-to-FCF. This places Ascendis Pharma AS in the lower half of its industry. The industry median EV-to-FCF is 14.97. Ascendis Pharma AS's value of 190.74 is 1174.1% above this benchmark. Historically, Ascendis Pharma AS's own EV-to-FCF has ranged from 196.30 to 229.52 over the past decade. While the company's 10-year median is 214.09 vs. the industry median of 14.97, Ascendis Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.97, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current EV-to-FCF of 190.74 is 1174.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current EV-to-FCF is 190.74, which is 11% below median its own 10-year median of 214.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current EV-to-FCF of 190.74. The current EV-to-FCF is 190.74, which is 11% below median its 10-year median of 214.09 and 1174.1% above the Biotechnology industry median of 14.97. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current EV-to-FCF is 190.74 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for MEX:ASNDN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ASNDN has been successfully added to your 
